Switching to Aflibercept in Diabetic Macular Edema Not Responding to Ranibizumab and/or Intravitreal Dexamethasone Implant

Table 6

Subgroup analysis of the impact of the preswitch VA (< or ≥70 letters) on CRT.

	Preswitch visual acuity
	VA < 70 letters (group 1)	VA ≥ 70 letters (group 2)	value^a (comparison between groups 1 and 2)
Number of eyes	17	8
Mean CRT in μm at baseline prior to any injection (SD)	582.7 (201.3)	430.5 (96.8)	0.03
Mean CRT in μm preswitch (SD)	495.2 (142.7)	418.9 (82)	0.28
Mean CRT postswitch M3 (SD)	312.7 (106)	321.6 (40.6)	0.47
Mean CRT postswitch M6 (SD)	301.8 (69.1)	306.4 (32.5)	0.62
F	18.21	9.42
value (ANOVA test)	<0.0001	0.003
value^b (comparison between CRT preswitch and M6 within each group)	0.0002	0.008

ANOVA test was performed to assess significance between CRT at baseline, preswitch, M3, and M6 after switch to aflibercept within each group. ^a values were obtained after an unpaired nonparametric Mann–Whitney test between groups 1 and 2 at each time point. ^b values were obtained after a paired nonparametric Wilcoxon test between preswitch CRT and CRT at M6 within each group. VA: visual acuity; CRT: central retinal thickness. <0.05; <0.01; <0.001; and <0.0001.